TP53 and glioblastoma: Inhibition of casein kinase 2 (CK2), as well as treatment with Sinomenine and betulinic acid derivative B10, has been shown to downregulate Sirt1, leading to enhanced p53 transcriptional activity and apoptosis induction in GBM cells [99, 100].